Headquartered in Cologne, Cevec provides high-performance cell line development and viral vector manufacturing technologies.

“Cevec's innovative technology complements Cytiva's offering and brings the promise of improved viral vector manufacturing. With Cytiva's global reach and ability to scale, more customers will have access to Cevec's technology and expertise to help accelerate and advance therapeutics for the benefit of patients,” said Emmanuel Abate, president, genomic medicine at the Massachusetts-based Danaher subsidiary.

Nicole Faust, Cevec’s CEO, added that the combination “enables the whole gene therapy industry to embark on new and powerful solutions for scalable vector manufacturing and start a new era for therapies made available to patients in need."

The companies explain that one of the pharmaceutical industry's biggest challenges in cell and gene therapy is establishing production processes that can keep up with the rising demand for volume and consistent quality of viral vectors.

With its scalable producer cell lines for vectors based on adeno-associated virus (AAV) and adenovirus, Cytiva said Cevec covers two of the most widely used vectors for delivering therapeutic genes to target cells and tissues.

Author: Elaine Burridge, Freelance Journalist